Skip to main content

Drug Interactions between encorafenib and Qualaquin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

quiNINE encorafenib

Applies to: Qualaquin (quinine) and encorafenib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quinine, which is primarily metabolized by the isoenzyme. The interaction has been studied with rifampin, a potent CYP450 3A4 inducer, and treatment failures have been reported. In patients with uncomplicated Plasmodium falciparum malaria who received quinine sulfate 10 mg/kg concomitantly with rifampin 15 mg/kg/day for 7 days, the median quinine systemic exposure (AUC) between days 3 and 7 of therapy was 75% lower than that observed in patients who received quinine monotherapy. Likewise, in nine healthy subjects who received a single 600 mg oral dose of quinine sulfate following pretreatment with rifampin 600 mg/day for 2 weeks, the mean quinine peak plasma concentration (Cmax) and AUC decreased by 55% and 85%, respectively. The extent to which other, less potent inducers of CYP450 3A4 may interact with quinine is unknown.

MANAGEMENT: Caution is advised if quinine is used in combination with CYP450 3A4 inducers such as carbamazepine, phenobarbital, phenytoin, and St. John's wort. The possibility of diminished therapeutic efficacy should be considered.

References

  1. Twum-Barima Y, Carruthers SG (1981) "Quinidine-rifampin interaction." N Engl J Med, 304, p. 1466-9
  2. (2001) "Product Information. Rifadin (rifampin)." Hoechst Marion Roussel
  3. Wanwimolruk S, Kang W, Coville PF, Viriyayudhakorn S, Thitiarchakul S (1995) "Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man." Br J Clin Pharmacol, 40, p. 87-91
  4. Pukrittayakamee S, Prakongpan S, Wanwimolruk S, Clemens R, Looareesuwan S, White NJ (2003) "Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria." Antimicrob Agents Chemother, 47, p. 1509-1513
  5. Fabre C, Criddle J, Nolder D, Klein JL (2005) "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg, 99, p. 871-3
  6. (2006) "Product Information. Qualaquin (quinine)." AR Scientific Inc
View all 6 references

Drug and food interactions

Major

encorafenib food

Applies to: encorafenib

You should preferably avoid consumption of grapefruit and grapefruit juice while taking encorafenib. Grapefruit and grapefruit juice can significantly increase the blood levels of encorafenib. This may increase the risk of serious side effects such as bleeding complications, eye and vision problems, liver problems, irregular heart rhythm, and development of new skin cancers. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Minor

quiNINE food

Applies to: Qualaquin (quinine)

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.